Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study
新型 EZH1/2 双重抑制剂 HH2853 在难治性实体瘤或非霍奇金淋巴瘤患者中的安全性和有效性:一项 I 期研究
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103398
Fan, Zhengfu; Wang, Jin; Liu, Dan; Shen, Lin; Fang, Meiyu; Johnson, Patrick; Tun, Han; Sommerhalder, David; Yang, Jilong; Yang, Yun; Munozi, Javier; Zhu, Jun; Gao, Tian; Li, Zhiming; Li, Xian'an; Ma, Qiuying; Lv, Chao; Yu, Songda; Li, Fugen; Song, Yuqin; Gong, Jifang